InsulinomaPhase 1/2GLP-1-AHHNCT03189953
68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH
A Phase 1/2 study testing 68Ga-NODAGA-exendin 4 PET/CT in people with Insulinoma, run by Radboud University Medical Center.
Trial summary
In order to improve the sensitivity and specificity of pre-operative imaging localization of foci in adult endogenous hyperinsulinemic hypoglycaemia (AHH) we aim to evaluate a novel promising imaging compound targeting the glucagon-like peptide-1 receptor (GLP-1R), 68Ga-NODAGA-exendin 4. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Insulinoma
- What is being tested?
- 68Ga-NODAGA-exendin 4 PET/CT
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- No sites listed yet
- Study dates
- Apr 2015to May 2021
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Biochemically proven endogenous hyperinsulinemic hypoglycemia
- Signed informed consent
- Standard imaging not older than 8 weeks.
Who cannot join
- Breast feeding
- Pregnancy or the wish to become pregnant within 6 months
- Calculated creatinine clearance below 40ml/min
- Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions)
- Age < 18 years
- No signed informed consent
About this study
Official title: 68Ga-NODAGA-exendin-4 PET/CT in Patients With AHH - a Prospective Comparative Evaluation of Preoperative Imaging
In order to improve the sensitivity and specificity of pre-operative imaging localization of foci in adult endogenous hyperinsulinemic hypoglycaemia (AHH) we aim to evaluate a novel promising imaging compound targeting the glucagon-like peptide-1 receptor (GLP-1R), 68Ga-NODAGA-exendin 4. With the currently used imaging techniques, only about 70-80% of insulin producing pancreatic neuroendocrine tumors (IPPNET) can be successfully visualized. Therefore, we propose to compare GLP-1R PET imaging to the standard imaging techniques in patients scheduled for surgical removal of the tumour. These highly relevant data will allow us to interpret the benefits of GLP-1R-imaging over other imaging techniques for the diagnosis of IPPNET in AHH patients. Since pre-operative localization of foci in AHH remains challenging and frequently still leading to futile surgery or unnecessary partial pancreatectomy, a more sensitive and specific imaging technique would be of great value.
Read the detailed description
Adult endogenous hyperinsulinaemic hypoglycaemia The most common form of functional neuroendocrine tumours of the pancreas are insulin producing pancreatic neuroendocrine tumors (IPPNET). These tumors are rare and have an incidence of 1-4 newly diagnosed cases per 1 million per year and are malignant in about 10% of the cases. Another cause of AHH is nesidioblastosis, or adult beta cell hyperplasia. It is difficult to exactly determine the incidence of the disease, but it appears that in approximately 5% of the cases of AHH nesiodioblastosis may be the underlying pathology, while IPPNET are responsible for the majority of the cases. The pathophysiological cause of nesidioblastosis is not well understood, but the rising incidence of the AHH as a consequence of gastric bypass surgery for morbid obesity (although often reversible in these patients) may suggest an association with metabolic and hormonal changes.
For IPPNET, surgical removal of the tumour is the therapy of choice and is considered curative in case of a benign tumour. Optimal preoperative localization of the lesion is warranted in order to reduce morbidity by helping to optimize the surgical procedure. Successful preoperative localization of IPPNET is a challenging problem since approximately 30% of IPPNET cannot be visualized using the conventional imaging techniques CT and/or MRI and endoscopic ultrasound. Selective arterial stimulation with calcium with simultaneous venous sampling (ASVS) has been described to have a sensitivity and specificity of almost 90% in identifying IPPNET. This is, however, an invasive technique which is accompanied by an risk for complications. Functional imaging with somatostatin (sst) receptor scintigraphy (SRS) and SPECT/CT are able to detect less than 50% of benign IPPNET because of low or absent expression of sst receptor subtypes 2 and 5, which bind octreotide with high affinity. PET with 68Ga-labeled sst analogs has a higher sensitivity for smaller lesions than SRS. Also 11C-5-HTP and 18F-DOPA, which are used as PET tracers for the detection of IPPNET in some centers may be more sensitive than SRS and CT with 11C-5-HTP showing the most accurate visualization. However, when compared to intra-operative findings, 2 out of 6 IPPNET could still not be detected preoperatively. Palpation and intra-operative ultrasound will allow identifying the lesion in approximately 70-80% of cases. However, it remains a challenge to find small or multiple tumours in the pancreas and partial pancreatectomy is frequently required, especially if the lesion is located close to the pancreatic duct. Precise preoperative localization of the IPPNET is therefore critical to minimize surgical intervention. If no IPPNET can be identified pre- or perioperatively, the diagnosis of nesidioblastosis may be established by resection and histopathologic evaluation of the pancreatic tail. If nesidioblastosis is present, partial pancreatectomy is required; the challenge is to remove enough tissue in order to avoid hypoglycaemia while keeping enough functional endocrine pancreatic tissue so that the patient does not become diabetic. Currently, with the risk of reoperation being considered lower than the consequences and complications of diabetes, surgeons usually choose a fairly conservative approach.
Imaging of diseased beta cells Visualization of the beta cells by a highly specific radiotracer with which high target-to background ratios can be obtained would benefit preoperative visualization of IPPNET in patients with AHH. Reliable visualization of diseased beta cells would then benefit the optimization of treatment of patients with AHH. An innovative method for imaging of beta cells could allow to optimally guide surgical interventions In addition, this novel approach could lead to a minimization of side-effects from the treatment.
Targeting of the GLP-1 receptor In this study we will compare the sensitivity and specificity of pre-operative imaging of IPPNET by GLP-1R scanning to the current standard imaging techniques.
- Conditions
- Insulinoma
- Being tested
- 68Ga-NODAGA-exendin 4 PET/CT
- Medical subject headings
- Insulinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
68Ga-NODAGA-exendin 4 PET/CTRadiation
68Ga-NODAGA-exendin 4 PET/CT
| Study group | Role | What they receive |
|---|---|---|
| 68Ga-NODAGA-exendin PET/CT | Experimental | 68Ga-NODAGA-exendin PET/CT Receives: Radiation: 68Ga-NODAGA-exendin 4 PET/CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging
Measured: 1 year
Secondary outcomes (4)
Calculation of the organ- and effective dose of 68Ga-NODAGA-exendin 4
Measured: 1 year
Retrospective surgery planning, type of surgery based on image analysis
Measured: 1 year
Calculation and comparison of the interobserver variability of 68Ga-NODAGA-exendin 4 PET/CT and EUS combined with triple phase CT or MRI
Measured: up to 24 months
GLP-1 receptor expression by histology compared to tracer uptake
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2017
- Study startApr 2015
- Primary completionJan 2021
- Study completionMay 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InsulinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Comparison of 68Ga-NODAGA-exendin PET/CT with standard diagnostic methods
- Masking
- None (open label)
- Enrolment
- 56 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Radboud University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- University Medical Center Groningen, Charite University, Berlin, Germany, University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, University College, London, University of Helsinki, University of Turku
- Responsible party
- Sponsor
- Investigators
- Martin Gotthardt, Prof. Dr., Principal investigator, Radboud University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03189953
- Sponsor's protocol ID
- NL50643.091.14
- Other IDs
- 2014-003167-38, 602812, 2014
- Acronym
- GLP-1-AHH
- Status last verified
- Jun 2021
- First submitted
- 6 Apr 2016
- Last updated
- 16 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 68Ga-NODAGA-exendin-4 PET/CT in Patients With AHH - a Prospective Comparative Evaluation of Preoperative Imaging
- ClinicalTrials.gov ID
- NCT03189953
- Acronym / sponsor ID
- GLP-1-AHH / NL50643.091.14
- Conditions
- Insulinoma
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (estimated)
- Lead sponsor
- Radboud University Medical CenterUniversity, hospital or other
- Collaborators
- University Medical Center Groningen, Charite University, Berlin, Germany, University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, University College, London, University of Helsinki, University of Turku
- Study start
- Apr 2015
- Primary completion
- Jan 2021 (actual)
- Study completion
- May 2021 (actual)
- First posted
- 16 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In order to improve the sensitivity and specificity of pre-operative imaging localization of foci in adult endogenous hyperinsulinemic hypoglycaemia (AHH) we aim to evaluate a novel promising imaging compound targeting the glucagon-like peptide-1 receptor (GLP-1R), 68Ga-NODAGA-exendin 4. With the currently used imaging techniques, only about 70-80% of insulin producing pancreatic neuroendocrine tumors (IPPNET) can be successfully visualized. Therefore, we propose to compare GLP-1R PET imaging to the standard imaging techniques in patients scheduled for surgical removal of the tumour. These highly relevant data will allow us to interpret the benefits of GLP-1R-imaging over other imaging techniques for the diagnosis of IPPNET in AHH patients. Since pre-operative localization of foci in AHH remains challenging and frequently still leading to futile surgery or unnecessary partial pancreatectomy, a more sensitive and specific imaging technique would be of great value.
Detailed description
Adult endogenous hyperinsulinaemic hypoglycaemia The most common form of functional neuroendocrine tumours of the pancreas are insulin producing pancreatic neuroendocrine tumors (IPPNET). These tumors are rare and have an incidence of 1-4 newly diagnosed cases per 1 million per year and are malignant in about 10% of the cases. Another cause of AHH is nesidioblastosis, or adult beta cell hyperplasia. It is difficult to exactly determine the incidence of the disease, but it appears that in approximately 5% of the cases of AHH nesiodioblastosis may be the underlying pathology, while IPPNET are responsible for the majority of the cases. The pathophysiological cause of nesidioblastosis is not well understood, but the rising incidence of the AHH as a consequence of gastric bypass surgery for morbid obesity (although often reversible in these patients) may suggest an association with metabolic and hormonal changes.
For IPPNET, surgical removal of the tumour is the therapy of choice and is considered curative in case of a benign tumour. Optimal preoperative localization of the lesion is warranted in order to reduce morbidity by helping to optimize the surgical procedure. Successful preoperative localization of IPPNET is a challenging problem since approximately 30% of IPPNET cannot be visualized using the conventional imaging techniques CT and/or MRI and endoscopic ultrasound. Selective arterial stimulation with calcium with simultaneous venous sampling (ASVS) has been described to have a sensitivity and specificity of almost 90% in identifying IPPNET. This is, however, an invasive technique which is accompanied by an risk for complications. Functional imaging with somatostatin (sst) receptor scintigraphy (SRS) and SPECT/CT are able to detect less than 50% of benign IPPNET because of low or absent expression of sst receptor subtypes 2 and 5, which bind octreotide with high affinity. PET with 68Ga-labeled sst analogs has a higher sensitivity for smaller lesions than SRS. Also 11C-5-HTP and 18F-DOPA, which are used as PET tracers for the detection of IPPNET in some centers may be more sensitive than SRS and CT with 11C-5-HTP showing the most accurate visualization. However, when compared to intra-operative findings, 2 out of 6 IPPNET could still not be detected preoperatively. Palpation and intra-operative ultrasound will allow identifying the lesion in approximately 70-80% of cases. However, it remains a challenge to find small or multiple tumours in the pancreas and partial pancreatectomy is frequently required, especially if the lesion is located close to the pancreatic duct. Precise preoperative localization of the IPPNET is therefore critical to minimize surgical intervention. If no IPPNET can be identified pre- or perioperatively, the diagnosis of nesidioblastosis may be established by resection and histopathologic evaluation of the pancreatic tail. If nesidioblastosis is present, partial pancreatectomy is required; the challenge is to remove enough tissue in order to avoid hypoglycaemia while keeping enough functional endocrine pancreatic tissue so that the patient does not become diabetic. Currently, with the risk of reoperation being considered lower than the consequences and complications of diabetes, surgeons usually choose a fairly conservative approach.
Imaging of diseased beta cells Visualization of the beta cells by a highly specific radiotracer with which high target-to background ratios can be obtained would benefit preoperative visualization of IPPNET in patients with AHH. Reliable visualization of diseased beta cells would then benefit the optimization of treatment of patients with AHH. An innovative method for imaging of beta cells could allow to optimally guide surgical interventions In addition, this novel approach could lead to a minimization of side-effects from the treatment.
Targeting of the GLP-1 receptor In this study we will compare the sensitivity and specificity of pre-operative imaging of IPPNET by GLP-1R scanning to the current standard imaging techniques.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Comparison of 68Ga-NODAGA-exendin PET/CT with standard diagnostic methods
| Arm | Type | Receives |
|---|---|---|
| 68Ga-NODAGA-exendin PET/CT | Experimental | Radiation: 68Ga-NODAGA-exendin 4 PET/CT68Ga-NODAGA-exendin PET/CT |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Biochemically proven endogenous hyperinsulinemic hypoglycemia
- Signed informed consent
- Standard imaging not older than 8 weeks.
Key exclusion criteria (6 listed)
- Breast feeding
- Pregnancy or the wish to become pregnant within 6 months
- Calculated creatinine clearance below 40ml/min
- Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions)
- Age < 18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 68Ga-NODAGA-exendin 4 PET/CT68Ga-NODAGA-exendin 4 PET/CT | Radiation | 68Ga-NODAGA-exendin PET/CT |
Primary outcome
Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging
Time frame: 1 year
4 secondary outcomes
Calculation of the organ- and effective dose of 68Ga-NODAGA-exendin 4
Time frame: 1 year
Retrospective surgery planning, type of surgery based on image analysis
Time frame: 1 year
Calculation and comparison of the interobserver variability of 68Ga-NODAGA-exendin 4 PET/CT and EUS combined with triple phase CT or MRI
Time frame: up to 24 months
GLP-1 receptor expression by histology compared to tracer uptake
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2021.
Related trials for Insulinoma
RecruitingObservational study
Diagnosing and Treating Low Blood Sugar Levels
Hypoglycemia, Insulinoma
RecruitingPhase 3
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Tumor Hyperinsulinism (Tumor HI)
Recruiting
Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization
Insulinoma
RecruitingObservational study
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
GLP1-R-related Disease, Tumor
RecruitingObservational study
Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Insulinoma; Pancreas
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Martin Gotthardt, Prof. Dr. principal investigator
Radboud University Medical Center
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing 68Ga-NODAGA-exendin 4 PET/CT in people with Insulinoma, run by Radboud University Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2021.